Asset Details
Do you wish to reserve the book?
Dual-mode action of scalable, high-quality engineered stem cell-derived SIRPα-extracellular vesicles for treating acute liver failure
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dual-mode action of scalable, high-quality engineered stem cell-derived SIRPα-extracellular vesicles for treating acute liver failure
Do you wish to request the book?
Dual-mode action of scalable, high-quality engineered stem cell-derived SIRPα-extracellular vesicles for treating acute liver failure
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dual-mode action of scalable, high-quality engineered stem cell-derived SIRPα-extracellular vesicles for treating acute liver failure
2025
Overview
Acute liver failure (ALF) is a life-threatening condition caused by rapid hepatocyte death and impaired liver regeneration. Here we show that extracellular vesicles engineered to express Signal Regulatory Protein Alpha (SIRP-EVs), produced via a scalable 3D bioreactor process with high yield and purity, exhibit significant therapeutic potential by targeting damaged cells and promoting tissue repair. SIRP-EVs block CD47, a crucial inhibitory signal on necroptotic cells, to enhance macrophage-mediated clearance of dying hepatocytes. They also deliver regenerative cargo from mesenchymal stem cells, reprogramming macrophages to support liver regeneration. In male animal models, SIRP-EVs significantly reduce liver injury markers and improve survival, demonstrating their dual-function therapeutic efficacy. By integrating the resolution of necroptosis with regenerative macrophage reprogramming, SIRP-EVs represent a promising platform for restoring liver function. These findings support the development of EV-based in vivo macrophage reprogramming therapies for ALF and other inflammation-driven diseases, paving the way for the clinical application of engineered EV therapeutics.
Acute liver failure arises from rapid cell death and impaired liver regeneration. Here, the authors show that scalable, high-purity engineered extracellular vesicles derived from stem cells promote the clearance of dying hepatocytes and drive liver repair through in vivo macrophage reprogramming.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/100
/ 13/31
/ 13/51
/ 14
/ 14/19
/ 38
/ 38/109
/ 45/91
/ 64/60
/ Animals
/ Antigens, Differentiation - genetics
/ Antigens, Differentiation - metabolism
/ Extracellular Vesicles - metabolism
/ Extracellular Vesicles - transplantation
/ Failure
/ Humanities and Social Sciences
/ Humans
/ Liver
/ Liver Failure, Acute - metabolism
/ Liver Failure, Acute - pathology
/ Liver Failure, Acute - therapy
/ Male
/ Mesenchymal Stem Cells - metabolism
/ Mice
/ Purity
/ Receptors, Immunologic - genetics
/ Receptors, Immunologic - metabolism
/ Science
/ Vesicles
